Sobrera Pharma AB announces 28 MSEK capital raise through a directed share issue to finance the continued development of SO-001, a new oral therapy for patients with Alcohol Use Disorder (AUD).

Sobrera Pharma AB, a clinical stage pharmaceutical company, successfully closed a private equity financing round at the end of 2020. Sobrera is developing new treatments for patients with substance use disorders with an initial focus on the product SO-001, currently in phase II development for the treatment of patients with moderate to severe Alcohol Use Disorder.

With a strong interest from both current owners and new investors the company raised, in an oversubscribed directed share issue, over 28 MSEK. The funds will allow Sobrera to continue build a strong franchise and to deliver activities such as formulation development and manufacturing of clinical trial material, preparation for a phase 1 study and validation of additional indications.

A phase II study is ongoing to assess the efficacy and safety of the new therapy. The study is being conducted at three clinical centers in Sweden, and will include 380 patients with AUD.